Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Director departure
|
|
Orgenesis Inc. (ORGS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/03/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/12/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/07/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/04/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"COMMON STOCK PURCHASE WARRANT orgenesis inc. Warrant Shares: _______ Initial Exercise Date: February 27, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February 27, 2023 and on or prior to 5:00 p.m. on February 28, 2028 but not thereafter, to subscribe for and purchase from Orgenesis Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that ...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 23, 2023, between Orgenesis Inc., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree a...",
"PLACEMENT AGENCY AGREEMENT February 23, 2023 Vered Caplan Chief Executive Officer Orgenesis Inc. 20271 Goldenrod Lane Germantown, MD 20876",
"Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering GERMANTOWN, Md., February 23, 2023 — Orgenesis, Inc. , a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,947,368 common stock and warrants to purchase up to 973,684 shares of common stock at a purchase price of $1.90 per share of common stock and accompanying warrants in a registered direct offering. The aggregate gross proceeds to the Company are expected to be approximately $3.7 million before deducting the placement agent’ s fees and other offering expenses payable by the Company. The warrants have an exercise price of $1.90 per share, are ex..." |
|
| 01/19/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/18/2023 |
8-K
| Quarterly results |
| 01/13/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/19/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
SC 13G
| New Dimensions Trading reports a 5.4% stake in Orgenesis, Inc. |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/27/2022 |
8-K
| Quarterly results |
| 08/17/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|